COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 3

Eficacia y seguridad de polihexanida 0. 1 % más undecilenamidopropil betaina 0. 1 % en pacientes con heridas crónicas en piel

INTRODUCCIÓN: El presente dictamen preliminar expone la evaluación de tecnología sanitaria (ETS) del antiséptico1 polihexanida 0.1 %, o polihexametilen biguanida, con betaína 0.1 % (PHMB), en solución o gel, en comparación con solución salina normal (SSN), para la limpieza de heridas crónicas en...

Low-intensity ultrasound (ExogenTM) for the treatment of fractures

Low-intensity ultrasound (Exogen™) is a home-based treatment for certain fractures and frac-ture complications. The Société de l'assurance automobile du Québec (SAAQ) asked the Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) to assess the efficacy and safety of t...

Informe técnico sobre cobertura de alprostadil en pie diabético isquémico

El Comité Farmacoterapéutico vigente del Hospital Nacional Arzobispo Loayza ha suspendido la aprobación del uso de alprostadil 20 ug amp, para la enfermedad arterial oclusiva periférica y para pie diabético isquémico, debido a que, al momento, la calidad de los estudios y la evidencia global dispon...